Patents Assigned to NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG
  • Novel therapeutical tools and methods for treating blindness
    Publication number: 20160250282
    Abstract: The present inventions relates to the use of an isolated nucleic acid molecule comprising a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence complementary to said nucleotide sequence, for treating or ameliorating blindness. The light-gated ion channel or pump gene can be a halorhodopsin gene.
    Type: Application
    Filed: January 25, 2016
    Publication date: September 1, 2016
    Applicant: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Resear
    Inventor: Rita HABAR
  • Method of treatment of breast cancers over-expressing the SHP2 signature genes
    Patent number: 9181553
    Abstract: A method for treating breast cancer in a subject having a breast cancer over-expressing the “SHP2 signature” genes, as compared to normal breast tissue samples, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2).
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: November 10, 2015
    Assignee: NOVARTIS FORSCHUNGSSTIFTUNG ZWEIGNIEDERLASSUNG FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Mohamed Bentires-Alj, Nicola Aceto, Michael Stadler
  • INHIBITION OF INTERLEUKIN-8 AND/OR ITS RECEPTOR CXCR1 IN THE TREATMENT OF HER2/HER3-OVEREXPRESSING BREAST CANCER
    Publication number: 20150266961
    Abstract: The present invention relates to a method for treating breast cancer in a subject having a breast cancer characterized by activation of the HER2/HER3 heterodimer, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of interleukin 8 (IL8) and/or of its receptor chemokine (C-X-C motif) receptor 1 (CXCR1).
    Type: Application
    Filed: March 27, 2013
    Publication date: September 24, 2015
    Applicant: NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG, FRIDRICH MIESCHER INSTITUTE
    Inventors: Mohamed Bentires-Alj, Nicola Aceto
  • Use of protease nexin 1 inhibitors to reduce metastasis
    Patent number: 8933212
    Abstract: The present invention relates to a method of inhibiting metastasis comprising the administration of an inhibitor of protease nexin-1 (PN-1), characterized in that said inhibitor is administered at a therapeutical dosage that does not completely inhibit the expression and/or activity of PN-1.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: January 13, 2015
    Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
    Inventors: Bérengère Fayard, Denis Monard
  • Rod cell-specific promoter
    Publication number: 20140287510
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 200 bp having at least 70% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: November 7, 2012
    Publication date: September 25, 2014
    Applicant: NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG FRIEDRICH MIESCHER INSTITUTE
    Inventors: Sandra Siegert, Josephine Juettner, Botond Roska
  • CULTURE MEDIUM SUITABLE FOR THE CULTURE OF UNDIFFERENTIATED CELLS
    Publication number: 20140178894
    Abstract: The present application relates to a composition comprising the components listed in Table I in an amount that will lead to the respective concentration specified in Table I for each of said component when said composition is diluted with water into 1× medium, said composition being particularly suitable to generate a chemically-defined medium suitable for culturing cells, especially primary cells, maintaining their proliferation and differentiation potential.
    Type: Application
    Filed: April 20, 2011
    Publication date: June 26, 2014
    Applicant: NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG
    Inventors: Mohamed Bentires-Alj, Stephan Duss
  • PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11 (PTPN11) AND TRIPLE-NEGATIVE BREAST CANCER
    Publication number: 20140134184
    Abstract: The present invention relates to a method for treating breast cancer in a subject having a breast cancer of the triple-negative type, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2).
    Type: Application
    Filed: June 5, 2012
    Publication date: May 15, 2014
    Applicant: NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG
    Inventors: Mohamed Bentires-Alj, Nicola Aceto, Michael Stadler
  • Teneurin and cancer
    Patent number: 8642280
    Abstract: The present invention relates to a method for treating cancer, for instance brain tumors, in a subject by inhibiting a teneurin by administering to said subject a therapeutically effective amount of a modulator of said teneurin, for example a specific antibody or a siRNA. The present invention also encompasses methods of diagnosing cancer by measuring levels of teneurin.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: February 4, 2014
    Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
    Inventors: Ruth Chiquet-Ehrismann, Daniela Kenzelmann Bro{hacek over (z)}
  • Genetic vasectomy by overexpression of PRML-EGFP fusion protein in spermatids
    Patent number: 8633348
    Abstract: The present invention provides a genetically-modified non-human animal whose somatic and germ cells contain an exogenous gene encoding a recombinant fusion protein, wherein the presence, and expression, of said recombinant fusion protein renders said genetically-modified non-human animal sterile. Tools for generating such sterile genetically-modified non-human animal as well as methods of use thereof are also provided.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: January 21, 2014
    Assignees: Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute for Biomedical Research, Universität Zürich
    Inventors: Pawel Pelczar, Thorsten Buch, Antoine Peters
  • TREATING CANCER BY MODULATING MAMMALIAN STERILE 20-LIKE KINASE 3
    Publication number: 20130089538
    Abstract: The present invention relates to a method for modulating miRNA, said method being characterized in that a modulator of XRN1 is used. Also provided are uses of said method for therapeutical purposes, reagents therefore, as well as screening methods.
    Type: Application
    Filed: June 9, 2011
    Publication date: April 11, 2013
    Applicant: Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh
    Inventors: Hauke Hermann Karl Cornils, Brian Arthur Hemmings, Mario Reinhard Stegert
  • MODULATING XRN1
    Publication number: 20130034543
    Abstract: The present invention relates to a method for modulating miRNA, said method being characterized in that a modulator of XRN1 is used. Also provided are uses of said method for therapeutical purposes, reagents therefore, as well as screening methods.
    Type: Application
    Filed: April 18, 2011
    Publication date: February 7, 2013
    Applicant: Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Resear
    Inventors: Saibal Chatterjee, Helge Grosshans
  • MODULATING XRN2
    Publication number: 20110300155
    Abstract: The present invention relates to a method for modulating miRNA, said method being characterized in that a modulator of XRN2 is used. Also provided are uses of said method for therapeutical purposes, reagents therefore, as well as screening methods.
    Type: Application
    Filed: December 3, 2009
    Publication date: December 8, 2011
    Applicant: NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG, F RIEDRICH MIESCHER INSTITUTE FOR BIOMWDICAL RESEAR
    Inventors: Saibal Chatterjee, Helge Grosshans
  • TREATING CANCER BY MODULATING MNK
    Publication number: 20110280886
    Abstract: The present invention relates to a method for treating cancer in a subject using a mTOR inhibitor in combination with a therapeutically effective amount of a modulator of a MNK.
    Type: Application
    Filed: November 11, 2009
    Publication date: November 17, 2011
    Applicants: UNIVERSITY HOSPITAL BASEL, NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG, F RIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEAR
    Inventors: Michal Grzmil, Brian Arthur Hemmings, Adrian Merlo, Pier Jr Morin
  • TREATING CANCER BY MODULATING RNA HELICASES
    Publication number: 20110262428
    Abstract: The present invention relates to a method for treating cancer in a subject by inhibiting DHX36, by administering to said subject a therapeutically effective amount of a modulator of DHX36.
    Type: Application
    Filed: September 22, 2009
    Publication date: October 27, 2011
    Applicant: NOVARTIS Forschungsstiftung Zweigniederlassung Fri -edrich Miescher Institute for Biomedical Researc
    Inventors: Mohamed Bentires-Alj, Yoshikuni Nagamine
  • NOVEL MITOCHONDRIAL DYE
    Publication number: 20110097731
    Abstract: The present invention relates to the use of single-barrel genetically encoded GFP-based calcium indicator as an intramitochondrial dye and to nucleic acid molecules coding for said indicators, as well as to methods using said indicators. Examples of single-barrel genetically encoded GFP-based calcium indicator is a GCaMP, Case16 and/or Case12. In a particular embodiment, the single-barrel genetically encoded GFP-based calcium indicator is GCaMP2 or Case16.
    Type: Application
    Filed: June 24, 2009
    Publication date: April 28, 2011
    Applicant: Novartis Forschungsstiftung, Zweigniederlassung Friedrich Mischer Institute for Biomedical Researc
    Inventors: Thomas Oertner, Tobias Rose
  • Purified PKB Ser 473 kinase and uses thereof
    Patent number: 7794995
    Abstract: This invention provides purified PKB Ser 473 kinase and methods of purifying it. The methods involve the use of several sequential steps, including subcellular fractionation to isolate a plasma membrane fraction and the use of gel filtration or chromatography that separates molecules according to their size or affinity.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: September 14, 2010
    Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
    Inventors: Jianhua Feng, Brian A Hemmings, Michelle M Hill
  • Neural Cell Differentiation Method From Es Cells
    Publication number: 20080171350
    Abstract: A method for inducing differentiation of embryonic stem cells into neuronal precursors is provided as well as an assay for neuronal precursor or progenitor cells and a method for identifying agents that inhibit or reduce an increase in neurite degeneration.
    Type: Application
    Filed: May 4, 2005
    Publication date: July 17, 2008
    Applicant: NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG FRIEDRICH MIESCHER INSTITU FOR BIOMEDICAL RESEARCH
    Inventors: Yves-Alain Barde, Miriam Bibel, Jens Richter, Kerry Lee Tucker
  • Tumour suppressor and uses thereof
    Patent number: 7396920
    Abstract: A human protein (designated Carboxy-terminal Modulating protein, CTMP) is described and is identified as having tumour suppressor properties. CTMP has been shown to interact with protein kinase B and inhibit protein kinase B activity, establishing its importance in the protein kinase B signalling pathway.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: July 8, 2008
    Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
    Inventors: Brian A Hemmings, Sauveur-Michel Maira
  • Protease-activated receptor (par) modulator assays
    Patent number: 7148018
    Abstract: There is provided a method of identifying a PAR cleaving molecule comprising the steps of: (a) providing an immobilized PAR cleavage peptide linked to a reporter molecule; (b) contacting the immobilized PAR cleavage peptide with a PAR cleaving molecule; and (c) detecting release of the reporter molecule.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: December 12, 2006
    Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
    Inventors: Ludger Altrogge, Denis Monard
  • Methods and reagents for protease inhibition
    Patent number: 7029877
    Abstract: There is provided a protease inhibitor and a method of inhibiting a protease selected from the group consisting of thrombin, chymotrypsin and neuropsin, by contacting the protease with an effective amount of a member of the phosphoethanolamine binding protein (PEBP) family.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: April 18, 2006
    Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Instittue for Biomedical Research
    Inventors: Hugo Albrecht, Ulrich Hengst, Denis Monard